July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
in vivo laser-mediated retinal ganglion cell optoporation using Kv1.1 conjugated gold nanoparticles
Author Affiliations & Notes
  • Ariel Wilson
    Biochemistry, Universite de Montreal, Montreal, Quebec, Canada
    Engineering Physics, Polytechnique Montreal, Montreal, Quebec, Canada
  • Javier Mazzaferri
    Ophthalmology, Universite de Montreal, Montreal, Quebec, Canada
  • Eric Bergeron
    Engineering Physics, Polytechnique Montreal, Montreal, Quebec, Canada
  • Sergiy Patskovsky
    Engineering Physics, Polytechnique Montreal, Montreal, Quebec, Canada
  • Santiago Costantino
    Ophthalmology, Universite de Montreal, Montreal, Quebec, Canada
  • Michel Meunier
    Engineering Physics, Polytechnique Montreal, Montreal, Quebec, Canada
  • Mike Sapieha
    Biochemistry, Universite de Montreal, Montreal, Quebec, Canada
  • Footnotes
    Commercial Relationships   Ariel Wilson, US 62/576,973 (P); Javier Mazzaferri, US 62/576,973 (P); Eric Bergeron, US 62/576,973 (P); Sergiy Patskovsky, None; Santiago Costantino, US 62/576,973 (P); Michel Meunier, US 62/576,973 (P); Mike Sapieha, US 62/576,973 (P)
  • Footnotes
    Support  CQDM, CHRP and NSERC
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 5694. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ariel Wilson, Javier Mazzaferri, Eric Bergeron, Sergiy Patskovsky, Santiago Costantino, Michel Meunier, Mike Sapieha; in vivo laser-mediated retinal ganglion cell optoporation using Kv1.1 conjugated gold nanoparticles. Invest. Ophthalmol. Vis. Sci. 2018;59(9):5694.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : There is a current void in efficient, cell-specific, retinal drug delivery systems, thus developing a safe, effective, selective drug delivery system would open novel therapeutic avenues. We previously demonstrated that femtosecond (fs) laser irradiation can transfect DNA plasmids into cultured cells in the presence of gold nanoparticles (AuNPs). These AuNPs locally amplify laser energy at a submicron range creating transient pores allowing exogenous genetic material or cell impermeable dyes to enter the cell. Here, we sought out to selectively optoporate retinal cells in vivo with functionalized AuNPs and a 800nm fs laser.

Methods : The cell-surface Kv1.1 voltage-gated channel was chosen to selectively target retinal ganglion cells (RGCs) in the rat retina. Citrate-capped spherical 100nm AuNPs functionalized with orthopyridyl-disulfide-poly(ethylene glycol) (5 kDa)-N-hydroxysuccinimide (OPSS-PEG-NHS) conjugated to a Kv1.1 monoclonal antibody were injected intravitreally in Sprague Dawley rats 3 hours prior to irradiation, concomitantly to a FITC-dextran dye to detect optoporation. The eyes of anesthetized rats were placed in the beam path of an optical system consisting of an 800 nm Ti:Sapphire 100 fs laser and a Heidelberg Spectralis HRA ophthalmoscope for fundus visualization. After irradiation, the rat retina the eyes were fixed in 4% paraformaldehyde, dissected, rinsed, mounted and imaged by confocal microscopy.

Results : Our novel laser system coupled to a Heidelberg ophthalmoscope allowed for a clear visualisation of the rat ocular fundus. A timecourse of AuNP intravitreal injections revealed that optimal nanoparticle dispersion on the retinal surface occurred at 3 hours post injection. Following Kv1.1-AuNP and FITC-dextran intravitreal injection and incubation, irradiation resulted in FITC uptake by retinal cells. Importantly, neither AuNP intravitreal injection nor irradiation resulted in RGC death, as determined by RBPMS quantification 1 week following AuNP injection and/or irradiation.

Conclusions : Since living biological tissues absorb energy very weakly at 800nm, this non-invasive tool may provide a safe, cost effective clinically relevant approach to locally and selectively target retinal cells and limit complications associated with surgical interventions, and potential biological hazards associated with viral-based gene therapy.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×